Strategic Relevance of OncoSil’s Presentation at DDW2025
1. Scientific Credibility and Global Platform
OncoSil’s clinical data was presented at Digestive Disease Week 2025 (DDW2025) in San Diego – one of the world’s largest and most respected conferences focused on gastroenterology, oncology, and gastrointestinal surgery. Hosted by four major US medical societies, DDW draws over 12,000 specialists from more than 70 countries, including:
Gastroenterologists and GI surgeons
Radiation and medical oncologists
Academic researchers and hospital clinical leads
Industry stakeholders and health system representatives
This presentation marks a significant validation of OncoSil’s clinical outcomes in a forum attended by global opinion leaders and frontline practitioners.
2. Visibility to the FDA
While the FDA does not exhibit at DDW, its representatives — particularly from the Oncology, Devices, and Drug Evaluation divisions — often attend scientific sessions to track innovation and engage informally with industry and clinicians. OncoSil’s presence at DDW therefore offers valuable indirect visibility to FDA stakeholders, which can support its ongoing regulatory positioning, including breakthrough designation and further US submissions.3. Engagement with Pharmaceutical Industry
Major US and multinational pharmaceutical companies are active attendees at DDW, including Pfizer, Merck, Bristol-Myers Squibb, J&J (Janssen), Roche, Amgen, AstraZeneca, AbbVie, and others. These companies participate to:
Identify novel therapeutic devices and adjunctive technologies
Monitor competitor pipelines
Evaluate licensing or co-development opportunities
Engage with clinical trial leaders and data
OncoSil’s positive survival and surgical conversion data — especially in comparison to SBRT — is well aligned with what pharma companies seek in next-generation oncology partnerships, particularly in the context of combination therapies for pancreatic and other GI cancers.
- Forums
- ASX - By Stock
- Ann: OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes
OSL
oncosil medical ltd
Add to My Watchlist
1.30%
!
$1.14

Strategic Relevance of OncoSil’s Presentation at DDW20251....
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $21.46M |
Open | High | Low | Value | Volume |
$1.16 | $1.16 | $1.14 | $32.51K | 28.26K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 14293 | $1.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.15 | 8971 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 14293 | 1.140 |
2 | 9405 | 1.135 |
1 | 2000 | 1.130 |
1 | 5000 | 1.120 |
2 | 5700 | 1.115 |
Price($) | Vol. | No. |
---|---|---|
1.150 | 8971 | 2 |
1.170 | 7380 | 1 |
1.190 | 25000 | 1 |
1.200 | 5000 | 1 |
1.205 | 1563 | 1 |
Last trade - 15.59pm 28/07/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |